NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









PDC*line Pharma

PDC*line Pharma

Private
LiègeHealthcare & Life Scienceshttps://www.pdc-line-pharma.com/

Last Round

Grant

Jan 17, 2024

Total Funding Raised

$26.98M

Company Overview

PDC*line Pharma is a biotechnology company that develops a class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

therapeutic cancer vaccineallogeneic cell therapyoff-the-shelf vaccinedendritic cell linecancer immunotherapyoff-the-shelfcell therapybiotech licensingoncology drug developmentclinical-stage biotechoff-the-shelf drugscancer vaxallogeneic

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PDC*line Pharma Comps

Public and private peers based on sector, stage, and business model.

PDC*line Pharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

PDC*line Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 17, 2024
Series B ExtensionDec 6, 2021
DebtJan 22, 2020
DebtDec 6, 2016

PDC*line Pharma Investors

Notable investors and investment history

PDC*line Pharma investors
InvestorRounds
Federal Holding and Investment CompanyDebt, Series B Extension
Korea Investment PartnersDebt, Series B Extension
NoshaqDebt, Series B Extension
Société Régionale d'Investissement de WallonieDebt, Series B Extension
Wallonie EntreprendreGrant
Brain Asset Management Co.,Ltd.Series B Extension
Korea Investment PartnersDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 6, 2021

    $14M round led by Korea Investment Partners.

  • Jan 22, 2020

    $22M round led by Korea Investment Partners.

PDC*line Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PDC*line Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PDC*line Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersLiège
Employee Range9
Year Founded2014
Last FundingJan 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.